Informace o publikaci
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
Autoři | |
---|---|
Rok publikování | 2021 |
Druh | Článek v odborném periodiku |
Časopis / Zdroj | Leukemia |
Fakulta / Pracoviště MU | |
Citace | |
www | https://www.nature.com/articles/s41375-021-01173-w.pdf |
Doi | http://dx.doi.org/10.1038/s41375-021-01173-w |
Klíčová slova | TKI discontinuation; CML; MMR-final report; AFTER-SKI |
Popis | Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited. |